# Vilya

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vilya

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.vilyatx.com
- Total disclosed funding: $71M
- Latest round: Series A (Aug 30, 2022)
- Investors on record: 6

## About

Founded in 2022 by David Baker, Gaurav Bhardwaj, Lance Stewart, Patrick Salveson, Adam Moyer, and Naozumi Hiranuma, and based in California, US, Vilya, Inc. operates as a biotechnology company that creates a new class of drugs that precisely target the biology of disease. In August 2022, Vilya, Inc. raised USD 71 million in series A funding led by new investor ARCH Venture Partners, with participation from other new investors NVentures, Menlo Ventures, Madrona Venture Group, LifeForce Capital, and Altitude Life Science Ventures. Other unspecified investors also participated in the round.

The company designs molecular structures with improved drug-like properties that range in size from small molecules to antibodies to create medicines by utilizing machine learning and uncharted chemical space.

## Funding rounds

- Series A, Aug 30, 2022, $71M — ARCH Venture Partners, Menlo Ventures, Madrona Venture Group, Altitude Life Science Ventures, Nventures, LifeForce Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A
- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series A
- Madrona Venture Group (https://capitalatlas.ai/funds/madrona-venture-group) — Series A
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series A
- Nventures — Series A
- LifeForce Capital (https://capitalatlas.ai/funds/lifeforce-capital) — Series A